BARDA

View All

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

As we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...

Find More

Clover gets fund; Libtayo for first-line Advanced NSCLC Subset
Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset

Clover Biopharmaceuticals Raises $230 Million  Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with partic...

Find More